

Nubega® (darolutamide) - Expanded indication

- On June 3, 2025, the <u>FDA announced</u> the approval of <u>Bayer's Nubeqa (darolutamide)</u>, for the treatment of adult patients with metastatic castration-sensitive prostate cancer (mCSPC).
- Nubeqa is also approved for the treatment of mCSPC, in combination with docetaxel, and for the treatment of non-metastatic castration resistant prostate cancer (nmCRPC).
- The approval of Nubeqa for the expanded indication was based on ARANOTE, a double-blind, placebo-controlled study in 669 patients with mCSPC. Patients were randomized to receive Nubeqa or placebo. The major outcome measure was radiographic progression-free survival (rPFS), defined as the time from randomization to radiological disease progression or death. An additional efficacy outcome measure was overall survival (OS).
 - Treatment with Nubeqa resulted in a statistically significant improvement in rPFS compared to placebo. Median rPFS was not reached with Nubeqa vs. 25 months with placebo (hazard ratio 0.54, 95% C: 0.41, 0.71; p < 0.0001).
 - There was no statistically significant improvement in OS.
- The recommended dose of Nubeqa is 600 mg (two 300 mg tablets) taken orally, twice daily.
 Treatment should be continued until disease progression or unacceptable toxicity occurs.
 - Patients receiving Nubeqa should also receive a gonadotropin-releasing hormone (GnRH) agonist or antagonist concurrently or have had a bilateral orchiectomy.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.